CO6290674A2 - Compuestos de 1,2,4-oxadiazol para el tratamiento de enfermedades autoinmunes - Google Patents
Compuestos de 1,2,4-oxadiazol para el tratamiento de enfermedades autoinmunesInfo
- Publication number
- CO6290674A2 CO6290674A2 CO10074469A CO10074469A CO6290674A2 CO 6290674 A2 CO6290674 A2 CO 6290674A2 CO 10074469 A CO10074469 A CO 10074469A CO 10074469 A CO10074469 A CO 10074469A CO 6290674 A2 CO6290674 A2 CO 6290674A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- formula
- pharmaceutically acceptable
- compounds
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con derivados novedosos de oxadiazol de fórmula (I) o una sal farmacéuticamente aceptables de los mismos, los compuestos de fórmula (I)y sus sales farmacéuticamente aceptables son de uso en el tratamiento de condiciones o trastornos que son mediados vía el receptor S1P1; en particular los compuestos de fórmula (I) y sus sales farmacéuticamente aceptables son de uso en el tratamiento de la esclerosis múltiple, enfermedades autoinmunes, trastornos inflamatorios crónicos, asma, neuropatías inflamatorias, artritis, transplante, enfermedad de Crohn, colitis ulcerativa, lupus eritematoso, soriasis, lesión por isquemia-reperfusión, tumores sólidos y metástasis del tumor, enfermedades asociadas con la angiogénesis, enfermedades vasculares, condiciones dolorosas, enfermedades virales agudas, condiciones inflamatorias del intestino, diabetes dependiente de la insulina y no dependiente de la insulina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0725102.8A GB0725102D0 (en) | 2007-12-21 | 2007-12-21 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6290674A2 true CO6290674A2 (es) | 2011-06-20 |
Family
ID=39048652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10074469A CO6290674A2 (es) | 2007-12-21 | 2010-06-21 | Compuestos de 1,2,4-oxadiazol para el tratamiento de enfermedades autoinmunes |
Country Status (19)
Country | Link |
---|---|
US (1) | US20100273770A1 (es) |
EP (1) | EP2220077A1 (es) |
JP (1) | JP2011506572A (es) |
KR (1) | KR20100108567A (es) |
CN (1) | CN101945865A (es) |
AU (1) | AU2008339993A1 (es) |
BR (1) | BRPI0821696A2 (es) |
CA (1) | CA2710055A1 (es) |
CO (1) | CO6290674A2 (es) |
CR (1) | CR11576A (es) |
DO (1) | DOP2010000193A (es) |
EA (1) | EA017669B1 (es) |
GB (1) | GB0725102D0 (es) |
IL (1) | IL206277A0 (es) |
MA (1) | MA31923B1 (es) |
NZ (1) | NZ585995A (es) |
UA (1) | UA101348C2 (es) |
WO (1) | WO2009080730A1 (es) |
ZA (1) | ZA201003965B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
WO2012019076A1 (en) * | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
EP2511275A1 (en) * | 2011-04-12 | 2012-10-17 | Bioprojet | Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists |
WO2014008257A2 (en) | 2012-07-02 | 2014-01-09 | Monsanto Technology Llc | Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles |
CN107827837B (zh) * | 2017-11-21 | 2021-09-24 | 苏州朗科生物技术股份有限公司 | 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070043014A1 (en) * | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
WO2005058848A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
JP2008517915A (ja) * | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | S1p受容体アゴニストとしての2−(アリール)アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
US20080306124A1 (en) * | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
CA2648303C (en) * | 2006-04-03 | 2014-07-15 | Astellas Pharma Inc. | 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists |
PE20091339A1 (es) * | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
-
2007
- 2007-12-21 GB GBGB0725102.8A patent/GB0725102D0/en not_active Ceased
-
2008
- 2008-12-19 AU AU2008339993A patent/AU2008339993A1/en not_active Abandoned
- 2008-12-19 US US12/747,198 patent/US20100273770A1/en not_active Abandoned
- 2008-12-19 JP JP2010538744A patent/JP2011506572A/ja active Pending
- 2008-12-19 WO PCT/EP2008/067972 patent/WO2009080730A1/en active Application Filing
- 2008-12-19 KR KR1020107016168A patent/KR20100108567A/ko not_active Application Discontinuation
- 2008-12-19 CN CN2008801273545A patent/CN101945865A/zh active Pending
- 2008-12-19 BR BRPI0821696-7A patent/BRPI0821696A2/pt not_active IP Right Cessation
- 2008-12-19 NZ NZ585995A patent/NZ585995A/xx not_active IP Right Cessation
- 2008-12-19 EP EP08863729A patent/EP2220077A1/en not_active Withdrawn
- 2008-12-19 EA EA201070783A patent/EA017669B1/ru not_active IP Right Cessation
- 2008-12-19 UA UAA201009201A patent/UA101348C2/ru unknown
- 2008-12-19 CA CA2710055A patent/CA2710055A1/en not_active Abandoned
-
2010
- 2010-06-03 ZA ZA2010/03965A patent/ZA201003965B/en unknown
- 2010-06-10 IL IL206277A patent/IL206277A0/en unknown
- 2010-06-16 MA MA32925A patent/MA31923B1/fr unknown
- 2010-06-21 DO DO2010000193A patent/DOP2010000193A/es unknown
- 2010-06-21 CO CO10074469A patent/CO6290674A2/es not_active Application Discontinuation
- 2010-07-21 CR CR11576A patent/CR11576A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DOP2010000193A (es) | 2010-08-15 |
WO2009080730A1 (en) | 2009-07-02 |
CN101945865A (zh) | 2011-01-12 |
AU2008339993A1 (en) | 2009-07-02 |
CR11576A (es) | 2010-09-03 |
EA017669B1 (ru) | 2013-02-28 |
BRPI0821696A2 (pt) | 2015-06-16 |
EP2220077A1 (en) | 2010-08-25 |
ZA201003965B (en) | 2011-03-30 |
JP2011506572A (ja) | 2011-03-03 |
CA2710055A1 (en) | 2009-07-02 |
IL206277A0 (en) | 2010-12-30 |
UA101348C2 (ru) | 2013-03-25 |
MA31923B1 (fr) | 2010-12-01 |
KR20100108567A (ko) | 2010-10-07 |
EA201070783A1 (ru) | 2010-12-30 |
NZ585995A (en) | 2012-12-21 |
US20100273770A1 (en) | 2010-10-28 |
GB0725102D0 (en) | 2008-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6290674A2 (es) | Compuestos de 1,2,4-oxadiazol para el tratamiento de enfermedades autoinmunes | |
CO2021008089A2 (es) | Agonistas de glp-1r y usos de los mismos | |
AR121016A2 (es) | Sales de fenotiazindiaminio y su uso | |
AR069916A1 (es) | Compuesto de oxadiazol, su uso para fabricar un medicamento, su uso para el tratamiento de enfermedades o trastornos mediados por los receptores s1p1 y composicion farmaceutica que lo comprende | |
AR064452A1 (es) | Derivados de 1,2,4 oxadiazol-indol,composiciones farmaceuticas que los comprenden y usos en trastornos asociados a receptores s1p1. | |
CL2011000777A1 (es) | Compuestos derivados de imidazopiridazina, inhibidor de proteína quinasa; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, psoriasis, artritis reumatoide, angiogenesis, entre otras. | |
AR067517A1 (es) | Anticuerpos inhibidores de la dimerizacion del receptor c-met (receptor del factor de crecimiento de hepatocitos hgf) y usos de los mismos | |
CL2008002787A1 (es) | Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil. | |
CO6480932A2 (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida. | |
AR077292A1 (es) | Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas | |
CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
ECSP088120A (es) | Derivados de piridazinona como agonistas del receptorde la hormona tiroidea | |
PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
CL2011001060A1 (es) | Compuestos derivados de 4-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil]-piridina, 3-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil)-fenilo, 3-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil)-fenilo; procedimiento de preparacion; composicion farmaceutica; utiles para tratar enfermedades cancerosas o tumorales. | |
JP2016508506A5 (es) | ||
MX2016015182A (es) | Compuestos triciclicos antidiabeticos. | |
CL2016000816A1 (es) | Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras. | |
UY32343A (es) | Compuestos de oxadiazol que inhiben dgat1 | |
JP2015502371A5 (es) | ||
AR062390A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas | |
AR085711A1 (es) | Compuesto de heteroaril oximetilen arilo sustituido, composicion farmaceutica y combinacion que lo comprenden y su uso para la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, cancer, una enfermedad inflamatoria y/o un trastorno alergico y una enfermedad asociada con la activacion inapropiada de las celulas cebadas | |
UY35393A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
CL2022001323A1 (es) | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x | |
UY31768A (es) | Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre | |
PE20200727A1 (es) | Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted | ||
FD | Application lapsed |